Reported Q: Q4 2024 Rev YoY: +46.3% EPS YoY: -11.8% Move: +0.03%
Centrus Energy Corp
LEU
$193.31 0.03%
Exchange NYSE Sector Energy Industry Uranium
Q4 2024
Published: Feb 7, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for LEU

Reported

Report Date

Feb 7, 2025

Quarter Q4 2024

Revenue

151.60M

YoY: +46.3%

EPS

3.20

YoY: -11.8%

Market Move

+0.03%

Previous quarter: Q3 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $151.60M up 46.3% year-over-year
  • EPS of $3.20 decreased by 11.8% from previous year
  • Gross margin of 40.8%
  • Net income of 53.70M
  • "“We are the only American company with a proven enrichment technology that would be able to enrich uranium up to just under 20% for HALEU and one of two companies with an NRC license to enrich LEU.”" - Amir Vexler
LEU
Company LEU

Swipe to view all report sections

Executive Summary

Centrus Energy reported a resilient Q4 2024 that capped a transformative year, underscored by robust revenue growth, stronger LEU and HALEU engagement, and a deliberate balance-sheet de-risking program. For the full year 2024, Centrus generated $442 million in revenue, up ~40% YoY, with gross profit of $111.5 million and operating income of $48 million. The company entered 2025 with a fortified liquidity position (ending cash of $671.4 million) and a lean pension obligation profile that reduced annual cash costs and enhanced optionality to deploy capital toward domestic enrichment capacity. Backlog remains healthy at $3.7 billion through 2040, including roughly $2.8 billion in LEU backlog and $0.9 billion in Technical Solutions backlog, reflecting a diversified revenue base across LEU, SWU, and HALEU activities. Management emphasized a first-mover US manufacturing advantage, a sizable contingent LEU sales program (approximately $2.0 billion), and a ramp plan tied to DOE task orders that, if realized, could meaningfully accelerate domestic enrichment capacity. The near-term catalysts include the November 2024 $60 million investment to restart centrifuge manufacturing at Oak Ridge, the late-2024 convertible notes closing (net proceeds ~$388.7 million), and a potential $62.4 million in investment tax credits tied to Oak Ridge manufacturing. However, the company faces meaningful execution and geopolitical risks, including timing of DOE task orders, ongoing license considerations with TENEX in Russia, and the broader transition of US-enriched uranium supply away from foreign dependencies. Overall, Centrus presents a compelling strategic positioning in a multi-year domestic enrichment cycle, with the potential to translate DOE-driven demand into a scalable, American-owned production platform over the next 2–4 years, subject to public funding and supply-chain execution.

Key Performance Indicators

Revenue
Increasing
151.60M
QoQ: 162.74% | YoY: 46.33%
Gross Profit
Increasing
61.80M
40.77% margin
QoQ: 594.38% | YoY: 24.10%
Operating Income
Increasing
45.10M
QoQ: 693.42% | YoY: 38.34%
Net Income
Decreasing
53.70M
QoQ: 1 174.00% | YoY: -4.62%
EPS
Decreasing
3.21
QoQ: 1 170.00% | YoY: -11.81%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q1 2025 73.10 1.60 +67.3% View
Q4 2024 151.60 3.20 +46.3% View
Q3 2024 57.70 -0.30 +12.5% View
Q2 2024 189.00 1.89 +92.1% View
Q1 2024 43.70 -0.38 -34.7% View